Firefly Bio specializes in the development of Degrader Antibody Conjugates (DACs), a novel approach that merges the advantages of traditional Antibody Drug Conjugates (ADCs) with selective protein degraders. This innovative technology allows for the precise delivery of degraders to targeted tissues, enhancing the therapeutic potential and specificity of treatments. Firefly's proprietary platform is designed to facilitate the exploration and utilization of new classes of ADC payloads, enabling the company to scale its operations effectively and address complex challenges in drug development.

The team at Firefly is composed of diverse innovators committed to advancing the field of biopharmaceuticals. Their collaborative and positive approach fosters an environment where impactful solutions can be developed, reflecting the company's mission to tackle significant medical challenges. By leveraging their unique technology and expertise, Firefly aims to redefine the landscape of antibody-based therapies and improve patient outcomes through targeted and effective treatment options.

United States

Firefly specializes in Degrader Antibody Conjugates (DACs) which combine the unique strengths of ADCs with selective protein degraders.

Firefly Bio

Company Details